Leucovorin and autism: Examining the evidence after a major trial retraction

The search for medications that might support autistic individuals has encountered new complexities. In February 2026, what was previously considered the largest clinical trial investigating leucovorin (folinic acid) was retracted due to implementation errors in data collection methods, as reported by The Transmitter. This 500-participant study (NCT03840475) had examined effects on communication differences.

Policy changes and evidence gaps

Following a September 2025 FDA clarification about existing prescribing pathways - not a new approval - leucovorin use increased. Some clinicians and families reported positive experiences, as noted in anecdotal accounts, though systematic evidence remains limited. An ongoing 120-child Phase 2 trial (completing 2027) may provide more robust data.

This 500-participant study (NCT03840475) had examined effects on communication differences.

Current pharmacological approaches

While no medication targets autism's core characteristics, the FDA has approved risperidone and aripiprazole for significant emotional distress including aggression in autistic youth, as detailed in a 2026 pharmacogenomics review. Research continues on multiple fronts, including animal studies of social processing and metabolic pathways.

Moving forward with care

The leucovorin case underscores the importance of rigorous research design and transparent reporting in autism studies. As autistic self-advocate Lydia Brown has noted, therapeutic development must center autistic priorities and experiences. Future studies will need to balance scientific rigor with respect for neurodiversity while addressing meaningful outcome measures.